Although previous clinical trials combating coagulation in ARDS did not produce convincing results [58], a decrease of coagulation in ARDS is the goal of ongoing trials studying heparin, antithrombin III, defibrotide, and tPA. Here, SERPINC1 is linked to acute respiratory distress syndrome.